BridgeBio Pharma (BBIO) Net Income towards Common Stockholders (2018 - 2026)
BridgeBio Pharma (BBIO) reported Net Income towards Common Stockholders of -$164.0 million for Q1 2026, up 2.02% on a YoY basis from -$160.8 million in Q1 2025, and up 14.94% sequentially from -$192.9 million in Q4 2025.
BridgeBio Pharma (BBIO) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$164.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 2.02% year-over-year to -$164.0 million; the trailing twelve-month figure through Mar 2026 stood at -$721.6 million (down 8.02% YoY), and the FY2025 full-year result was -$724.9 million, down 35.31% from the prior year.
- Net Income towards Common Stockholders advanced to -$164.0 million in Q1 2026, from -$192.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$9.9 million in Q2 2022 to a low of -$265.0 million in Q4 2024.
- A 5-year average of -$149.9 million and a median of -$164.0 million in 2026 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders jumped 89.77% in 2022 and sank 1502.06% in 2023, its largest moves.
- Tracing BBIO's Net Income towards Common Stockholders over 5 years: stood at -$137.6 million in 2022, then retreated by 22.21% to -$168.1 million in 2023, then plunged by 57.63% to -$265.0 million in 2024, then increased by 27.24% to -$192.9 million in 2025, then gained by 14.94% to -$164.0 million in 2026.
- Business Quant data shows BBIO's Net Income towards Common Stockholders at -$164.0 million in Q1 2026, -$192.9 million in Q4 2025, and -$182.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | -0.68 |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 205.99 Mn |
| 10 | BridgeBio Pharma | 16.45 Bn | 15.51 Bn | 184.58 Mn | -164.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -164.04 Mn |
| Dec 31, 2025 | -192.86 Mn |
| Sep 30, 2025 | -182.74 Mn |
| Jun 30, 2025 | -181.90 Mn |
| Mar 31, 2025 | -167.42 Mn |
| Dec 31, 2024 | -265.05 Mn |
| Sep 30, 2024 | -162.04 Mn |
| Jun 30, 2024 | -73.46 Mn |
| Mar 31, 2024 | -35.22 Mn |
| Dec 31, 2023 | -168.15 Mn |
| Sep 30, 2023 | -177.00 Mn |
| Jun 30, 2023 | -157.90 Mn |
| Mar 31, 2023 | -140.16 Mn |
| Dec 31, 2022 | -137.59 Mn |
| Sep 30, 2022 | -137.34 Mn |
| Jun 30, 2022 | -9.86 Mn |
| Mar 31, 2022 | -196.40 Mn |
| Dec 31, 2021 | -147.18 Mn |
| Sep 30, 2021 | -155.94 Mn |
| Jun 30, 2021 | -96.35 Mn |